Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

639

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Hypertension
Interventions
DRUG

telmisartan 80 mg + hydrochlorothiazide 25 mg

Trial Locations (78)

112

Boehringer Ingelheim Investigational Site, Taipei

1685

Boehringer Ingelheim Investigational Site, Midrand

2000

Boehringer Ingelheim Investigational Site, Soweto

2001

Boehringer Ingelheim Investigational Site, Newtown

2033

Boehringer Ingelheim Investigational Site, Lenasia

Boehringer Ingelheim Investigational Site, Lenasia South

2610

Boehringer Ingelheim Investigational Site, Saint-Imier

3460

Boehringer Ingelheim Investigational Site, Birker?d

4001

Boehringer Ingelheim Investigational Site, Durban

4031

Boehringer Ingelheim Investigational Site, Basel

4051

Boehringer Ingelheim Investigational Site, Basel

6500

Boehringer Ingelheim Investigational Site, Bellinzona

6940

Boehringer Ingelheim Investigational Site, Vezia

7531

Boehringer Ingelheim Investigational Site, Bellville

8300

Boehringer Ingelheim Investigational Site, Odder

11407

Hospital Gral de Jerez de la Frontera, Jerez de La Frontera / Cadiz

15706

Hospital del Conxo, Santiago de Compostela

27043

Ospedale Arnaboldi, Broni (pv)

28007

Hospital Univ. Gregorio Mara?on, Madrid

28935

Hospital de Mostoles - Medicina Interna, Mostoles / Madrid

31029

Ospedale Civile, Vittorio Veneto (tv)

44100

Azienda Ospedaliera Universita di Ferrara, Ferrara

48680

Hospital de Galdakao, Galdakao / Vizcaya

49000

ALTI, Angers

55218

Boehringer Ingelheim Investigational Site, Ingelheim

60323

Boehringer Ingelheim Investigational Site, Frankfurt am Main

63110

Boehringer Ingelheim Investigational Site, Rodgau-Dudenhofen

65439

Boehringer Ingelheim Investigational Site, Flörsheim

73485

Boehringer Ingelheim Investigational Site, Unterschneidheim

75000

Mg Recherches, Paris

75015

Mg Recherches, Paris

83527

Boehringer Ingelheim Investigational Site, Haag

90402

Boehringer Ingelheim Investigational Site, Nuremberg

93000

Hopital Avicenne, Bobigny

93586

Boehringer Ingelheim Investigational Site, Kuching, Sarawak

134701

Boehringer Ingelheim Investigational Site, Seoul

152703

Boehringer Ingelheim Investigational Site, Seoul

405760

Boehringer Ingelheim Investigational Site, Incheon

DK-6100

Boehringer Ingelheim Investigational Site, Haderslev

DK-2600

Boehringer Ingelheim Investigational Site, R?dovre

DK-7480

Boehringer Ingelheim Investigational Site, Vildbjerg

FI-00500

Boehringer Ingelheim Investigational Site, Helsinki

FI-80100

Boehringer Ingelheim Investigational Site, Joensuu

FI-20100

Boehringer Ingelheim Investigational Site, Turku

FI-20520

Boehringer Ingelheim Investigational Site, Turku

08236

Boehringer Ingelheim Investigational Site, Ellefeld

Unknown

Boehringer Ingelheim Investigational Site, Hong Kong

Boehringer Ingelheim Investigational Site, Birr

Boehringer Ingelheim Investigational Site, Carrigallen

Boehringer Ingelheim Investigational Site, Dublin

Boehringer Ingelheim Investigational Site, Gorey

Boehringer Ingelheim Investigational Site, Mallow

Boehringer Ingelheim Investigational Site, New Ross

Boehringer Ingelheim Investigational Site, Templeshannon

00163

IRCCS San Raffaele, Roma

7685 PG

Boehringer Ingelheim Investigational Site, Beerzeveld

2121 BB

Boehringer Ingelheim Investigational Site, Bennebroek

6644 CL

Boehringer Ingelheim Investigational Site, Ewijk

1817 BG

Boehringer Ingelheim Investigational Site, Hoogwoud

7441 BN

Boehringer Ingelheim Investigational Site, Nijverdal

9665 AR

Boehringer Ingelheim Investigational Site, Oude Pekela

9665 BJ

Boehringer Ingelheim Investigational Site, Oude Pekela

2281 AK

Boehringer Ingelheim Investigational Site, Rijswijk

2371 RB

Boehringer Ingelheim Investigational Site, Roelofarendsveen

3082 DC

Boehringer Ingelheim Investigational Site, Rotterdam

N-2408

Boehringer Ingelheim Investigational Site, Elverum

N-2391

Boehringer Ingelheim Investigational Site, Moelv

N-0369

Boehringer Ingelheim Investigational Site, Oslo

N-2020

Boehringer Ingelheim Investigational Site, Skedsmokorset

0038

Boehringer Ingelheim Investigational Site, Pretoria

08911

Hospital Municipal de Badalona, Badalona

08902

C.A.P. Mosen Cinto Verdaguer, L'Hospitalet de Llobregat / Barcelona

08303

C.A.P. Ronda Cerdanya, Mataro / Barcelona

575 36

Boehringer Ingelheim Investigational Site, Eksjö

651 85

Boehringer Ingelheim Investigational Site, Karlstad

652 24

Boehringer Ingelheim Investigational Site, Karlstad

451 40

Boehringer Ingelheim Investigational Site, Uddevalla

751 25

Boehringer Ingelheim Investigational Site, Uppsala

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00267943 - Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients | Biotech Hunter | Biotech Hunter